Phase 3CompletedAge-related condition
Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms
Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients
- Sponsor
- Upsher-Smith Laboratories (Industry)
- Enrolment
- 495 enrolled
- Conditions
- Postmenopausal Symptoms
- Interventions
- Divigel
- Ages
- adults, older adults
- Registry
- NCT00727129
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to compare the safety and efficacy of USL-221 to placebo for postmenopausal patients.
Primary outcomes
- Daily frequency and severity of moderate to severe vasomotor symptoms
History
Last registry update
Registered
Study completion
Started